ORLY MISHAN
CIK 1830911 · Chief Business Officer · last filed 2026-08-12
ORLY MISHAN is a Chief Business Officer who has filed 3 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing, for ADGM, was dated Aug 12, 2026.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
2
3
$0
Filer Profile
131 DARTMOUTH STREET SUITE 502
BOSTON, MA 02116
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ADGM | Director | — | $0.56 | — | $0 | 2 | 2026-08-12 |
| Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | Chief Business Officer | 38,450 | $18.07 | $694.8K | $0 | 1 | 2021-01-28 |
Recent Filings
3 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-12 | ADGM | Grant (A) | — | $0 | EDGAR |
| 2025-03-21 | ADGM | Grant (A) | — | $0 | EDGAR |
| 2021-01-28 | Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | Exer (M) | +38,450 | $134.6K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.